NASDAQ:PRQR - ProQR Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.67 +0.16 (+0.86 %)
(As of 11/14/2018 03:47 AM ET)
Previous Close$18.51
Today's Range$17.96 - $19.20
52-Week Range$2.75 - $24.00
Volume160,497 shs
Average Volume204,525 shs
Market Capitalization$738.69 million
P/E Ratio-9.62
Dividend YieldN/A
Beta0.54
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRQR
Previous Symbol
CUSIPN/A
Phone31-88-166-7000

Debt

Debt-to-Equity Ratio0.06
Current Ratio11.39
Quick Ratio11.39

Price-To-Earnings

Trailing P/E Ratio-9.62
Forward P/E Ratio-13.53
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.39 per share
Price / Book13.43

Profitability

EPS (Most Recent Fiscal Year)($1.94)
Net Income$-49,320,000.00
Net MarginsN/A
Return on Equity-74.20%
Return on Assets-57.03%

Miscellaneous

Employees130
Outstanding Shares38,720,000
Market Cap$738.69 million
OptionableOptionable

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics NV (NASDAQ:PRQR) announced its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.10. View ProQR Therapeutics' Earnings History.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for ProQR Therapeutics.

What price target have analysts set for PRQR?

4 analysts have issued 1 year target prices for ProQR Therapeutics' stock. Their forecasts range from $9.00 to $40.00. On average, they expect ProQR Therapeutics' share price to reach $26.00 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price. View Analyst Price Targets for ProQR Therapeutics.

What is the consensus analysts' recommendation for ProQR Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ProQR Therapeutics.

What are Wall Street analysts saying about ProQR Therapeutics stock?

Here are some recent quotes from research analysts about ProQR Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ". Initiating at OW and $40 12-month PT. ProQR is a European RNA-based platform technology company focused on developing therapeutics for inherited blindness. Although shares are up close to 500% YTD (vs. XBI down 9%) after positive proof of concept in first ophthalmology drug QR-110, we think this could be just the beginning of a major turning point for the company’s platform. In September, ProQR established the first proof of concept for its RNA platform in inherited ophthalmology with lead asset QR-110. We think QR-110 could be just the tip of the iceberg in terms of PRQR’s platform potential in inherited forms of blindness. In this report, we are focused on the company’s next clinical program in Usher’s Syndrome which represents a larger opportunity than QR-110 (we estimate $1.1B peak vs. $300M peak) and is guided to have clinical data in 2019." (11/13/2018)
  • 2. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (11/7/2018)
  • 3. HC Wainwright analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $18.0/ share, as a 25x multiple of taxed and diluted $9.92 discounted back to FY18 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $21.9/ share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (10/30/2018)

Has ProQR Therapeutics been receiving favorable news coverage?

News stories about PRQR stock have trended negative this week, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ProQR Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a increase in short interest in October. As of October 31st, there was short interest totalling 985,408 shares, an increase of 60.6% from the October 15th total of 613,551 shares. Based on an average daily volume of 254,800 shares, the days-to-cover ratio is currently 3.9 days. Currently, 3.7% of the company's shares are sold short. View ProQR Therapeutics' Current Options Chain.

Who are some of ProQR Therapeutics' key competitors?

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the folowing people:
  • Mr. Daniel A. de Boer, CEO & Member of Management Board (Age 35)
  • Mr. Rene K. Beukema, Chief Corp. Devel. Officer, Gen. Counsel, Corp. Sec. & Member-Management Board (Age 54)
  • Ms. Smital Shah, Chief Financial Officer (Age 42)
  • Mr. Joost Clement, Director of HR
  • Mr. Bart Klein, Sr. VP of Intellectual Property

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (7.78%), Artal Group S.A. (3.37%), FMR LLC (2.20%), Monashee Investment Management LLC (0.28%), Credit Suisse AG (0.19%) and Franklin Street Advisors Inc. NC (0.16%).

Which institutional investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Essex Investment Management Co. LLC, Franklin Street Advisors Inc. NC and Credit Suisse AG.

Which institutional investors are buying ProQR Therapeutics stock?

PRQR stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Monashee Investment Management LLC and Jennison Associates LLC.

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $18.67.

How big of a company is ProQR Therapeutics?

ProQR Therapeutics has a market capitalization of $738.69 million. The biopharmaceutical company earns $-49,320,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ProQR Therapeutics employs 130 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is http://www.proqr.com.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]


MarketBeat Community Rating for ProQR Therapeutics (NASDAQ PRQR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel